Skip to main content

Yangtze River Pharma Signs $338 Million Deal for Gastro Reflux Therapy

Yangtze River Pharma signed a $338 million deal for China rights to a gastroesophageal reflux treatment from South Korea 's Daewoong Pharma. Fexuprazan is a novel potassium-competitive acid blocker (P-CAB) developed by Daewoong, which blocks the proton pump that secretes gastric acids from the stomach wall. Daewonong successfully completed a Korean Phase III clinical trial for the therapy in 2019. The agreement includes an $18 million upfront payment and $12 million in development milestones. More details.... Share this with colleagues: // //
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.